Rhaleb N E, Télémaque S, Rouissi N, Dion S, Jukic D, Drapeau G, Regoli D
Medical School, University of Sherbrooke, Quebec, Canada.
Hypertension. 1991 Jan;17(1):107-15. doi: 10.1161/01.hyp.17.1.107.
Thirty-seven compounds were tested as antagonists of kinin B2- and B1-receptors to identify the chemical changes required to obtain antagonism, improve antagonist affinity, and eliminate residual agonistic activities. Apparent affinity of antagonists was evaluated in terms of pA2 on the rabbit jugular vein, the dog carotid and renal arteries, the hamster urinary bladder, the guinea pig ileum, the rat vas deferens, the guinea pig trachea, and the rabbit aorta, using bradykinin and desArg9-bradykinin as B2- and B1-receptor activators. Replacement of Pro7 of bradykinin with D-Phe leads to antagonism; substitution of Pro3 by Hyp and extension of the peptide chain at the N-terminal with a D-Arg residue improves the affinity of antagonists; acetylation of N-terminal amine function reduces residual agonistic activity; these changes, combined with the replacement of Phe8 by Leu as in Ac-D-Arg[Hyp3,D-Phe7,Leu8]-bradykinin, led to potent full B2-receptor antagonists. Affinity of antagonists differs markedly between highly sensitive (rabbit jugular vein, dog carotid and renal artery), moderately sensitive (hamster urinary bladder, guinea pig ileum, and rat vas deferens), and insensitive preparations (the guinea pig trachea) in which antagonists act as potent stimulants. High concentrations of antagonists block bradykinin completely in the rabbit jugular vein but not in the guinea pig ileum, suggesting that kinins stimulate the moderately sensitive tissues by two mechanisms, of which only one is blocked by antagonists. It thus appears that kinins act on various B2-receptor subtypes or by different action mechanisms.
测试了37种化合物作为激肽B2和B1受体的拮抗剂,以确定获得拮抗作用、提高拮抗剂亲和力和消除残余激动活性所需的化学变化。使用缓激肽和去精氨酸9-缓激肽作为B2和B1受体激活剂,根据pA2在兔颈静脉、犬颈动脉和肾动脉、仓鼠膀胱、豚鼠回肠、大鼠输精管、豚鼠气管和兔主动脉上评估拮抗剂的表观亲和力。将缓激肽的Pro7替换为D-苯丙氨酸可导致拮抗作用;用Hyp取代Pro3并在N端用D-精氨酸残基延长肽链可提高拮抗剂的亲和力;N端胺功能的乙酰化可降低残余激动活性;这些变化与将Phe8替换为亮氨酸(如在Ac-D-Arg[Hyp3,D-Phe7,Leu8]-缓激肽中)相结合,产生了强效的完全B2受体拮抗剂。拮抗剂的亲和力在高敏制剂(兔颈静脉、犬颈动脉和肾动脉)、中度敏感制剂(仓鼠膀胱、豚鼠回肠和大鼠输精管)和不敏感制剂(豚鼠气管)之间有显著差异,在不敏感制剂中拮抗剂表现为强效刺激剂。高浓度的拮抗剂可完全阻断兔颈静脉中的缓激肽,但不能阻断豚鼠回肠中的缓激肽,这表明激肽通过两种机制刺激中度敏感组织,其中只有一种机制可被拮抗剂阻断。因此,激肽似乎作用于各种B2受体亚型或通过不同的作用机制发挥作用。